Recent advances in nanoparticle-based drug delivery systems for rheumatoid arthritis treatment

Nasra, Simran; Bhatia, Dhiraj; Kumar, Ashutosh

doi:10.1039/d2na00229a

Cited by 36 publications

(17 citation statements)

References 125 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results were consistent with previous reports that cellular membrane-coated NPs had good biosafety. , Conventional drug delivery systems (DDS) were shown to have disadvantages including high dose requirement, poor bioavailability, and unexpected drug toxicity. , NP-based targeted DDS could selectively deliver drug to specific sites and target cells, thus reducing drug consumption and side effects . These NPs have gained increasing application in RA treatment. , Our results also illustrated that ATRA-Gol-PMMNP treatment safely and effectively alleviated synovial inflammation and cartilage degradation in a rat model of RA. Nevertheless, the dosing schedule and time interval between repeated injections of ATRA-Gol-PMMNPs warrant further optimization to facilitate its translation to clinical setting.…”

Section: Resultssupporting

confidence: 91%

“…78,79 NP-based targeted DDS could selectively deliver drug to specific sites and target cells, thus reducing drug consumption and side effects. 80 These NPs have gained increasing application in RA treatment. 80,81 Our results also illustrated that ATRA-Gol-PMMNP treatment safely and effectively alleviated synovial inflammation and cartilage degradation in a rat model of RA.…”

Section: Atra-gol-pmmnps Reduce Multiple Pathogenic Mediators Produce...mentioning

confidence: 99%

“…80 These NPs have gained increasing application in RA treatment. 80,81 Our results also illustrated that ATRA-Gol-PMMNP treatment safely and effectively alleviated synovial inflammation and cartilage degradation in a rat model of RA. Nevertheless, the dosing schedule and time interval between repeated injections of ATRA-Gol-PMMNPs warrant further optimization to facilitate its translation to clinical setting.…”

Section: Atra-gol-pmmnps Reduce Multiple Pathogenic Mediators Produce...mentioning

confidence: 99%

See 2 more Smart Citations

Engineered Platelet Microparticle-Membrane Camouflaged Nanoparticles for Targeting the Golgi Apparatus of Synovial Fibroblasts to Attenuate Rheumatoid Arthritis

et al. 2022

View full text Add to dashboard Cite

Synovial fibroblasts in rheumatoid arthritis (RA) joints mediate synovial hyperplasia, progressive joint destruction, and the potential spread of disease between joints by producing multiple pathogenic proteins. Here, we deliver all-trans retinoic acid (ATRA) to selectively down-regulate these pathogenic factors, with a Golgi-targeting platelet microparticle-mimetic nanoplatform (termed Gol-PMMNP) which comprises a nanoparticle core and a platelet microparticle membrane coating labeled with a Golgi apparatus-targeting peptide. Gol-PMMNPs are shown to target synovial fibroblasts derived from RA patients via integrin α2β1-mediated endocytosis and accumulate in the Golgi apparatus by retrograde transport. ATRA-loaded Gol-PMMNPs (ATRA-Gol-PMMNPs) cause structural disruption of the Golgi apparatus, leading to an efficient reduction of pathogenic protein secretion in RA synovial fibroblasts. In rats with collagen-induced arthritis, Gol-PMMNPs display an arthritic joint-specific distribution, and ATRA-Gol-PMMNPs effectively reduce concentrations of pathogenic factors therein, including inflammatory cytokines, chemokines, and matrix-degrading enzymes within these joints. Additionally, ATRA-Gol-PMMNP treatment results in inflammatory remission and decreased bone erosion in both arthritic and proximal joints. Furthermore, ATRA-Gol-PMMNPs induce negligible toxicity to major organs. Taken together, ATRA-Gol-PMMNPs inhibit the progression of RA through reducing the production of multiple pathogenic mediators by synovial fibroblasts.

show abstract

Section: Resultssupporting

confidence: 91%

Section: Atra-gol-pmmnps Reduce Multiple Pathogenic Mediators Produce...mentioning

confidence: 99%

Section: Atra-gol-pmmnps Reduce Multiple Pathogenic Mediators Produce...mentioning

confidence: 99%

See 1 more Smart Citation

Engineered Platelet Microparticle-Membrane Camouflaged Nanoparticles for Targeting the Golgi Apparatus of Synovial Fibroblasts to Attenuate Rheumatoid Arthritis

et al. 2022

View full text Add to dashboard Cite

show abstract

“…They possess the capacity to encapsulate both lipophilic and hydrophilic active ingredients, thereby making them an exceptionally favorable choice in drug delivery. 32 The bioavailability of curcumin is enhanced when it is formulated with liposomes, micelles, and phospholipids, primarily because of its high affinity for lipid-based systems. 33 Liposomal curcumin was discovered to be two to six times more potent than corresponding curcuminoids.…”

Section: Introductionmentioning

confidence: 99%

Reprogramming M1-to-M2 Phenotype to Alleviate Inflammation: Using Liposomal Curcumin as a Tool to Redefine Macrophage Functionality

Nasra

Shah

Bhatt

et al. 2023

ACS Appl. Bio Mater.

Self Cite

View full text Add to dashboard Cite

The versatile nature of macrophages and their ability to switch between various activation states plays a pivotal role in both promoting and inhibiting inflammatory processes. In pathological inflammatory conditions, classically activated M1 macrophages are often associated with initiating and maintaining inflammation, while alternatively activated M2 macrophages are linked to the resolution of chronic inflammation. Achieving a favorable equilibrium between M1 and M2 macrophages is crucial for mitigating inflammatory environments in pathological conditions. Polyphenols are known to have strong inherent antioxidative capabilities, and curcumin has been found to reduce macrophage inflammatory reactions. However, its therapeutic efficacy is compromised due to its poor bioavailability. The present study aims to harness the properties of curcumin by loading it in nanoliposomes and enhancing the M1-to-M2 macrophage polarization. A stable liposome formulation was achieved at 122.1 ± 0.08 nm, and a sustained kinetic release of curcumin was observed within 24 h. The nanoliposomes were further characterized using TEM, FTIR, and XRD, and the morphological changes in macrophage cells, RAW264.7, were observed in SEM, indicating a distinct M2-type phenotype after the treatment with liposomal curcumin. ROS may partially control macrophage polarization and be observed to decrease after treatment with liposomal curcumin. The nanoliposomes were able to successfully internalize in the macrophage cells, and an enhanced expression of ARG-1 and CD206 with a decrease in iNOS, CD80, and CD86 levels suggested the polarization of LPS-activated macrophages toward the M2 phenotype. Also, liposomal curcumin treatment dose-dependently inhibited TNF-α, IL-2, IFN-γ, and IL-17A at secretory levels and simultaneously increased the levels of cytokines like IL-4, IL-6, and IL-10.

show abstract

“…In this case, polydopamine (PDA) was introduced to overcome the stability of nanomaterials, which plays the role of encapsulating and slowly releasing drugs because PDA can form an adhesive layer onto the surface of MSN and have good biocompatibility and biodegradability . Generally, the permeation and accumulation of unmodified MSN into arthritic joints happens through inflamed leaky capillaries, an effect known as enhanced permeability and retention. , However, unmodified nanocarriers can also be cleared quickly by the reticulo-endothelial system (RES) before reaching the inflamed joints . Hence, surface modifications of nanocarriers for escaping from RES and active targeting of immune cells are constantly being explored …”

Section: Introductionmentioning

confidence: 99%

Ultrasound-Targeted Microbubble Destruction-Mediated Cell-Mimetic Nanodrugs for Treating Rheumatoid Arthritis

Guo

Wang

Huang

et al. 2023

ACS Biomater. Sci. Eng.

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is an autoimmune disease that mainly affects joints, and it can lead to disability and damage to vital organs if not diagnosed and treated in time. However, all current therapeutic agents for RA have limitations such as high dose, severe side effects, long-term use, and unsatisfactory therapeutic effects. The long-term use and dose escalation of methotrexate (MTX) may cause mild and severe side effects. To overcome the limitations, it is critical to target drug delivery to the inflamed joints. In this work, we constructed a folic acidtargeted and cell-mimetic nanodrug, MTX-loaded mesoporous silica composite nanoplatform (MMPRF), which can regulate drug release under ultrasound (US) and microbubble (MB) mediation. The targeted delivery and drug therapy were investigated through in vitro RAW264.7 cell experiments and in vivo collageninduced arthritis animal experiments. The result showed that the targeting ability to the joints of MMPRF was strong and was more significant after US and MB mediation, which can potently reduce joint swelling, bone erosion, and inflammation in joints. This work indicated that the US-and MB-mediated MMPRF not only would be a promising method for synergistic targeted treatment of RA but also may show high potential for serving as a nanomedicine for many other biomedical fields.

show abstract

Recent advances in nanoparticle-based drug delivery systems for rheumatoid arthritis treatment

Abstract: Nanotechnology has increasingly emerged as a promising tool for exploring new approaches, from treating complex conditions to early detection of the onset of multiple disease states. Tailored designer nanoparticles can...

Cited by 36 publications

References 125 publications

Engineered Platelet Microparticle-Membrane Camouflaged Nanoparticles for Targeting the Golgi Apparatus of Synovial Fibroblasts to Attenuate Rheumatoid Arthritis

Engineered Platelet Microparticle-Membrane Camouflaged Nanoparticles for Targeting the Golgi Apparatus of Synovial Fibroblasts to Attenuate Rheumatoid Arthritis

Reprogramming M1-to-M2 Phenotype to Alleviate Inflammation: Using Liposomal Curcumin as a Tool to Redefine Macrophage Functionality

Ultrasound-Targeted Microbubble Destruction-Mediated Cell-Mimetic Nanodrugs for Treating Rheumatoid Arthritis

Contact Info

Product

Resources

About